Cargando…

Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis

BACKGROUND: Small studies have implicated plasminogen activator inhibitor-1 (PAI-1) as a predictor of cardiovascular events; however, these findings have been inconsistent. We sought out to examine the potential role of PAI-1 as a marker for major adverse cardiovascular events (MACE). METHODS: We sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Richard G., Motazedian, Pouya, Ramirez, F. Daniel, Simard, Trevor, Di Santo, Pietro, Visintini, Sarah, Faraz, Mohammad Ali, Labinaz, Alisha, Jung, Young, Hibbert, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987541/ https://www.ncbi.nlm.nih.gov/pubmed/29991926 http://dx.doi.org/10.1186/s12959-018-0166-4

Ejemplares similares

Female Authorship in Preclinical Cardiovascular Research: Temporal Trends and Influence on Experimental Design
por: Labinaz, Alisha, et al.
Publicado: (2019)

Progenitor Cells for Arterial Repair: Incremental Advancements towards Therapeutic Reality
por: Simard, Trevor, et al.
Publicado: (2017)

Efficacy of Milrinone and Dobutamine in Cardiogenic Shock: An Updated Systematic Review and Meta-Analysis
por: Abdel-Razek, Omar, et al.
Publicado: (2023)

Dipyridamole and vascular healing following stent implantation
por: Simard, Trevor, et al.
Publicado: (2023)

The balloon impasse sign in percutaneous transvenous mitral valvuloplasty
por: Simard, Trevor, et al.
Publicado: (2020)

Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations
por: Simard, Trevor, et al.
Publicado: (2019)

Association Between Self‐Reported Potentially Modifiable Cardiac Risk Factors and Perceived Need to Improve Physical Health: A Population‐Based Study
por: Ramirez, F. Daniel, et al.
Publicado: (2017)

Plasminogen Activator Inhibitor-1–Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype
por: Jung, Richard G., et al.
Publicado: (2022)

Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk
por: Simard, Trevor, et al.
Publicado: (2020)

Journal Initiatives to Enhance Preclinical Research: Analyses of Stroke, Nature Medicine, Science Translational Medicine
por: Ramirez, F. Daniel, et al.
Publicado: (2020)

Contrast-free optical coherence tomography:Systematic evaluation of non-contrast media for intravascular assessment
por: Simard, Trevor, et al.
Publicado: (2020)

Methodological Rigor in Preclinical Cardiovascular Studies: Targets to Enhance Reproducibility and Promote Research Translation
por: Ramirez, F. Daniel, et al.
Publicado: (2017)

Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock
por: Jung, Richard G., et al.
Publicado: (2021)

Safety of same-day discharge in patients with left main percutaneous intervention
por: Abdel-Razek, Omar, et al.
Publicado: (2022)

Modifiable Risk Factors and Residual Risk Following Coronary Revascularization: Insights From a Regionalized Dedicated Follow-Up Clinic
por: Simard, Trevor, et al.
Publicado: (2021)

Methodological quality of COVID-19 clinical research
por: Jung, Richard G., et al.
Publicado: (2021)

Diagnostic accuracy of point-of-care ultrasound with artificial intelligence-assisted assessment of left ventricular ejection fraction
por: Motazedian, Pouya, et al.
Publicado: (2023)

Impact of atrial fibrillation on the risk of major adverse cardiac events following coronary revascularisation
por: Jung, Richard G, et al.
Publicado: (2022)

Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial
por: Marbach, Jeffrey A., et al.
Publicado: (2022)

Selective serotonin reuptake inhibitors and cardiovascular events: A systematic review
por: Nezafati, Mohammad Hassan, et al.
Publicado: (2016)

Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial
por: Di Santo, Pietro, et al.
Publicado: (2021)

De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes
por: Barry, Quinton, et al.
Publicado: (2021)

Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR)
por: Di Santo, Pietro, et al.
Publicado: (2023)

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
por: Waschki, Benjamin, et al.
Publicado: (2017)

Antidepressants and cardiovascular adverse events: A narrative review
por: Nezafati, Mohammad Hassan, et al.
Publicado: (2015)

Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
por: D'Elia, John A., et al.
Publicado: (2016)

New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults—a multicenter retrospective cohort study
por: Fernando, Shannon M., et al.
Publicado: (2020)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

A Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention: The CAPITAL RELOAD Study
por: Hibbert, Benjamin, et al.
Publicado: (2014)

Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD
por: Sommerer, Claudia, et al.
Publicado: (2023)

Circadian rhythm of plasminogen activator inhibitor-1 and cardiovascular complications in type 2 diabetes
por: Yu, Yongzhuo, et al.
Publicado: (2023)

The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
por: Pieters, Marlien, et al.
Publicado: (2017)

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
por: Saes, Joline L., et al.
Publicado: (2019)

Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms
por: Kim, Eun Ran, et al.
Publicado: (2013)

Utility of a smartphone application in assessing palmar circulation prior to radial artery harvesting for coronary artery bypass grafting: rationale and design of the randomised CAPITAL iRADIAL-CABG trial
por: Goh, Cheng Yee, et al.
Publicado: (2022)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Retraction: The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
Publicado: (2018)

Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy
por: Andersen, Matilde Kanstrup, et al.
Publicado: (2023)

Planning and Promoting events in Health Sciences Libraries: Success Stories and Best Practices (book review)
por: Visintini, Sarah
Publicado: (2021)

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
por: Seok, Su-Jin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3ceem3dq1sjijd8quunomnv75i